Search market news

* Retension Pharmaceuticals Plans to Use Remainder of Net Proceeds for General Corporate Purposes, Other Operating Expenses >RTSN

(END) Dow Jones Newswires October 08, 2026 21:58 ET (01:58 GMT) Copyright (c) 2026 Dow Jones & Company, Inc. The statements in this document shall not be considered as an objective or independent explanation of the matters. Please note that this document (a) has not been prepared in accordance with legal requirements d

Retension Pharmaceuticals plans to use remaining net proceeds

Retension Pharmaceuticals prices upsized IPO at $12 a share

Retension Pharmaceuticals priced its upsized initial public offering at $12.00 a share for 3,750,000 common shares. The company expects gross proceeds of $45.0 million before expenses and says trading should begin on Oct. 9 on Nasdaq under RTSN.